Scholars Central

Conference abstract

Strategies and innovation in biosimilar drug development, achievement and challenges ? An Indian perspective

Authors: Villoo Morawala-Patell

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Hatim Motiwala is a postgraduate in Microbiology and at completion stage of Ph.D. from The M.S. University of Baroda, India. He has 12 years of experience working on biosimilars. His core expertise is in mammalian cell culture with working experience in cell line development, mammalian upstream process development, in-vitro bioassays, technology evaluation and transfer. Currently, working at a post of Senior Scientist and managing three biosimilar monoclonal antibody development programs at Intas Biopharmaceutical Limited. Earlier he was associated with Biocon Biopharmaceuticals, Cadila Pharmaceuticals, Sun Pharma Advanced Research Centre, and Chiron Vaccines Limited (Aventis).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Villoo Morawala-Patell”